Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The report reveals extensive insights concerning over 100 companies and more than 110 drugs within the Atopic Dermatitis (AD) landscape. This analysis examines therapeutic assessments by product type, development stage, route of administration, and molecule category, as well as specifics on inactive pipeline products. The report's coverage is global, providing a comprehensive understanding of AD.
This report offers a thorough commercial overview, focusing on collaborations, licensing, and acquisitions. It provides a comparative assessment of companies based on therapy type, development stage, and technology. Key questions address current treatments versus emerging therapies, highlighting novel approaches in the pipeline.
Market leaders across the US, Europe, and Japan present topical solutions, including emollients and corticosteroids, and advanced systemic treatments like Dupixent. Highlighting pipeline innovations, the report details significant clinical trials and partnerships targeting novel therapeutic developments.
Report Highlights:
- In April 2023, Aldeyra Therapeutics initiated a Phase II trial for ADX 629 for treating AD.
- Q32 Bio and Horizon Therapeutics started a Phase II study of ADX-914 in October 2022.
- Nektar Therapeutics shared data on rezpegaldesleukin in September 2022 at the EADV Congress.
- Other significant collaborations include Pfizer's acquisition of Arena Pharmaceuticals and Amgen's agreement on KHK4083 development with Kyowa Kirin.
Key Company Profiles:
- Incyte: Based in Wilmington, Delaware, Incyte focuses on addressing severe medical needs through proprietary therapeutics. The company's expertise in immunology, particularly the JAK-STAT pathway, is driving innovation in AD treatments with OPZELURA, a topical JAK1/JAK2 inhibitor.
- LEO Pharma: A Denmark-headquartered leader in dermatology, LEO Pharma provides a diverse range of treatments. Their product, ADTRALZA, targets IL-13 cytokine interactions involved in AD and is approved for various international markets.
- Cara Therapeutics: Known for pioneering kappa opioid receptor agonists, Cara Therapeutics is developing Difelikefalin for AD, which is advancing through Phase III trials.
- Kyowa Kirin: As a noted specialty pharmaceutical company, Kyowa Kirin is innovating antibody-based treatments across multiple conditions, including AD, with KHK4083 in Phase II trials.
- Bayer: Bayer's Zabedosertib, an IRAK4 inhibitor under Phase II development, promises an innovative approach to managing inflammatory responses in AD.
- Alphyn Biologics: With its AB-101 platform, Alphyn is advancing the first dual-action therapeutics for AD, addressing inflammatory and bacterial challenges through a multi-target approach.
Key Players & Products:
- Major players include Eli Lilly, Vanda Pharmaceuticals, and Dermavant Sciences.
- Highlighted products are Lebrikizumab, Tradipitant, Roflumilast, and CBP-201.
Key Topics Covered:
Introduction
Executive Summary
Atopic dermatitis: Overview
- Introduction
- Classification
- Risk factors
- Diagnosis
- Treatment
Atopic dermatitis - Analytical Perspective: In-depth Commercial Assessment
- Atopic dermatitis Collaboration Analysis by Companies
Competitive Landscape
- Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Atopic dermatitis: Company and Product Profiles (Marketed Therapies)
Incyte
- Company Overview
OPZELURA
- Product Description
- Research and Development Activities
- Product Developmental Activities
Atopic dermatitis: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
- Comparative Analysis
Cara Therapeutics
- Company Overview
Difelikefalin
- Product Description
- Research and Development Activities
- Product Developmental Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Bayer
- Company Overview
Zabedosertib
- Product Description
- Research and Development Activities
- Product Developmental Activities
Early Stage Products (Phase I)
- Comparative Analysis
Merck Sharp & Dohme LLC
- Company Overview
MK-6194
- Product Description
- Research and Development Activities
- Product Developmental Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Company Name
Product Name
- Product Description
- Research and Development Activities
- Product Developmental Activities
Inactive Products
- Comparative Analysis
Atopic dermatitis- Unmet needs
Atopic dermatitis - Market drivers and barriers
Appendix
Companies Featured
- Eli Lilly and Company
- Vanda Pharmaceuticals
- Arcutis Biotherapeutics
- Suzhou Connect Biopharmaceuticals
- Dermavant Sciences, Inc.
- Suzhou Zelgen Biopharmaceuticals
- Reistone Biopharma
- Kyowa Kirin
- Cara Therapeutics
- Kangstem Biotech
- Arena Pharmaceuticals
- Bellus Health
- Tioga Pharmaceutical
- BioMimetix
- Botanix Pharmaceuticals
- AOBiome
- Aclaris Therapeutics
- Asana BioSciences
- Sanofi
- Horizon Therapeutics
- Evommune
- Celgene Corporation
- Allakos Inc.
- Bayer
- Alphyn Biologics
- Argenx
- Shulov Innovate for Science
- Teres Bio
- Qurient Co
- Sun Pharmaceutical
- Pfizer
- Ichnos Sciences
- Shaperon
- Pyramid Bioscience
- selectiON
- GSK
- Avixgen Inc
- Brexogen
- Fresh Tracks Therapeutics
- Yuhan Corporation
- Ribon Therapeutics
- Biosion
- HK inno.N Corporation
- NovaCell Technology Inc.
- Inmagene Biopharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/3paeyl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
